Response to “Comment on ‘Cannabinoids in dermatologic surgery’”

Abstract

Response to ''Comment on 'Cannabinoids in dermatologic surgery'''To the Editor: We thank Fazzari et al 1 for their interest in our article 2 and for their comments. We agree that we were not able to fully discuss the extensive scope of all cannabinoids and their effects and we therefore appreciate that in their comments they emphasized the diversity of the cannabinoids and some of the distinguished effects of non-cannabidiol (CBD) cannabinoids.We are grateful to Fazarri et al 1 for alerting us to a typographical error in the manuscript, where ''cannabinoids'' was unfortunately incorrectly replaced by ''CBD.'' The paragraph, ''Therapeutic applications of CBD'' should have been entitled ''Therapeutic applications of cannabinoids'' and the term ''CBD'' in that paragraph, in Fig 1, as well as in the sentence, ''Further studies would be necessary to characterize the impact of the drug interactions of CBD on patient outcomes'' should have been replaced by the word ''cannabinoids.'' We regret that we were not able to catch this editorial error earlier and the confusion that it caused.We also read with much interest the reports on the use of topical cannabis-based medicines on wound closure and healing. 3,4 This was also pointed out by Abdalla et al 5 in their recent commentary. Based on the available preliminary data, we agree that topical cannabis-based medicines hold much potential and eagerly await the results of larger randomized trials in multiple types of wounds.We wholeheartedly agree that both CBD and non-CBD cannabinoids hold significant promise for the treatment of dermatologic conditions, although for the purposes of our review, we focused primarily on implications for dermatologic surgery. At a minimum, we are excited about continued dialogue regarding this thrilling field of research and discovery and its impact on the field.